KEVIN DANIEL COX
Pilots at Camden Wood Ct, Raleigh, NC

8034916, Oct 11, 2011

Oct 19, 2009

12/581752

Lynn F. Dickey - Cary NC, US
Kevin M. Cox - Raleigh NC, US
Charles G. Peele - Apex NC, US

Biolex Therapeutics, Inc. - Pittsboro NC

C07H 21/04, A01H 5/00, C12N 15/05, C12N 15/82

536 241, 536 234, 536 236, 800298, 800295, 800278, 800288, 435468, 435419

Compositions and methods for regulating expression of nucleotide sequences of interest in a plant are provided. Compositions include novel nucleic acid molecules, and variants and fragments thereof, for expression control elements isolated from the ubiquitin, r-histone and chitinase genes. A method for expressing a nucleotide sequence of interest in a plant using the expression control elements disclosed herein is further provided. The method includes introducing into a plant or plant cell or nodule an expression construct comprising an expression control element of the present invention operably linked to a nucleotide sequence of interest. In particular, the compositions and methods find use in enhancing expression of nucleotide sequences of interest in duckweed. Also provided is a novel signal peptide-encoding sequence and the signal peptide encoded thereby. Where an expression construct of the invention is designed to express a polypeptide of interest, this novel signal peptide-encoding sequence can be included within the expression construct of the invention to provide for extracellular secretion of the encoded polypeptide of interest.

2008006, Mar 6, 2008

Jan 17, 2007

11/624158

Lynn Dickey - Cary NC, US
Kevin Cox - Raleigh NC, US
Charles Peele - Apex NC, US
Ming-Bo Wang - Kaleen, AU

Biolex, Inc. - Pittsboro NC

A01H 5/00, C07H 21/04, C07K 14/00, C07K 16/18, C12N 15/00, C12N 15/82, C12N 5/04

800276000, 435320100, 435410000, 530386000, 530387100, 536023500, 536023600, 800286000, 800288000, 800298000

Methods for altering the N-glycosylation pattern of proteins in higher plants are provided. The methods comprise introducing into the plant a recombinant construct that provides for the inhibition of expression of α1,3-fucosyltransferase (FucT) and β1,2-xylosyltransferase (XylT) in a plant. Use of these constructs to inhibit or suppress expression of both of these enzymes, and isoforms thereof, advantageously provides for the production of endogenous and heterologous proteins having a “humanized” N-glycosylation pattern without impacting plant growth and development. Stably transformed higher plants having this protein N-glycosylation pattern are provided. Glycoprotein compositions, including monoclonal antibody compositions, having substantially homogeneous glycosylation profiles, and which are substantially homogeneous for the G0 glycoform, are also provided.

8017836, Sep 13, 2011

Dec 22, 2009

12/644640

David Spencer - Chapel Hill NC, US
Lynn F. Dickey - Cary NC, US
John R. Gasdaska - Carrboro NC, US
Xiaowei Wang - Carrboro NC, US
Kevin M. Cox - Raleigh NC, US
Charles G. Peele - Apex NC, US

Biolex Therapeutics, Inc. - Pittsboro NC

A01H 5/00, C12N 15/82, C12N 5/04, C12N 5/10, C12N 15/12, C12N 15/62

800288, 435 696, 435 698

The present invention provides methods and compositions for the production of recombinant plasminogen, microplasminogen, and fragments thereof in a duckweed expression system. It is the novel finding of the present invention that a duckweed expression system may be used to produce high levels of plasminogen and microplasminogen. The duckweed-produced plasminogen and microplasminogen can be activated to produce a polypeptide having protease activity. Thus, the invention encompasses methods for the expression of plasminogen, microplasminogen, and fragments thereof in duckweed, duckweed plants that are transformed with expression cassettes for the expression of plasminogen, microplasminogen, and fragments thereof, and nucleic acids comprising nucleotide sequences encoding plasminogen, microplasminogen, and fragments thereof, where these nucleotide sequences are modified to enhance their expression in duckweed.

2009006, Mar 5, 2009

May 5, 2008

12/115133

Lynn F. Dickey - Cary NC, US
Kevin M. Cox - Raleigh NC, US
Charles G. Peele - Apex NC, US
Ming-Bo Wang - Kaleen, AU

Biolex Therapeutics, Inc. - Pittsboro NC

A61K 39/395, C07K 16/18, C12N 5/04, A61P 31/00

4241521, 5303871, 4241721, 435410

Glycan-optimized monoclonal antibodies that specifically bind CD20 antigen and which have improved effector function are provided. The anti-CD20 antibodies of the invention have a glycosylation pattern that results in an antibody composition having predominately the G0 glycoform, and thus comprise N-glycans that lack fucose (i.e., afucosylated) and galactose residues attached thereto. In some embodiments, these anti-CD20 antibodies comprise the light chain and heavy chain sequences of the rituximab anti-CD20 antibody, and thus represent afucosylated rituximab. Methods for producing these glycan-optimized anti-CD20 antibodies are also provided.

8022270, Sep 20, 2011

Sep 30, 2003

10/675011

Lynn Dickey - Cary NC, US
John Gasdaska - Carrboro NC, US
Kevin Cox - Raleigh NC, US

Biolex Therapeutics, Inc. - Pittsboro NC

C12N 15/82, C12N 15/87, A01H 5/00

800288, 800278, 435468

Methods, nucleic acid sequences, and transformed duckweed plant or duckweed nodule cultures for the expression and the secretion of biologically active polypeptides from genetically engineered duckweed are provided. Expression of recombinant polypeptides in duckweed is improved by modifying the nucleotide sequence of the expression cassette encoding the polypeptide for improved expression in duckweed. Recovery of biologically active polypeptides from duckweed is improved by linking the biologically active polypeptide to a signal peptide that directs the secretion of the polypeptide into the culture medium.

2005004, Feb 24, 2005

Jun 30, 2004

10/881813

Kevin Cox - Raleigh NC, US
Charles Peele - Apex NC, US

Biolex, Inc. - Pittsboro NC

A01H001/00, C12N015/82, A01H009/00

800288000, 800295000

The present invention provides methods and compositions for the transformation of duckweed plastids. The compositions and methods of the invention are useful in increasing the recombinant protein production capacity of the duckweed expression system. The compositions of the invention include transformed duckweed plastids and transplastomic duckweed cells and plants, as well as nucleic acid constructs useful for transforming duckweed plastids. The invention also provides methods for introducing one or more heterologous nucleotide sequences into a duckweed plastome.

2012027, Nov 1, 2012

Apr 18, 2012

13/449417

Amelia Nancy BLACK - Los Gatos CA, US
David B. PASSMORE - San Carlos CA, US
Mohan SRINIVASAN - Cupertino CA, US
Lynn F. DICKEY - Cary NC, US
Kevin M. COX - Raleigh NC, US
Charles G. PEELE - Apex NC, US
Ming-Bo WANG - Canberra, AU

MEDAREX, INC. - Princeton NJ
BIOLEX THERAPEUTICS, INC. - Pittsboro NC

C07K 16/28, C12N 5/071, A61P 37/04, A61K 35/00, A61P 35/02, C12N 5/10, A61K 39/395

4241331, 435419, 435375, 5303873

The invention pertains to anti-CD30 antibodies that lack fucosyl and xylosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated and xylosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl and xylosyl residues, wherein the host cells are deficient for a fucosyltransferase and a xylosyltransferase. Methods of using the antibodies to inhibit the grown of CD30cells, such as tumor cells, are also provided.

7959910, Jun 14, 2011

Apr 16, 2004

10/574046

Lynn Dickey - Cary NC, US
John Gasdaska - Chapel Hill NC, US
Kevin Cox - Raleigh NC, US

Biolex Therapeutics, Inc. - Pittsboro NC

A61K 38/21, C07K 14/56, C12P 21/02, C07H 21/04, C12N 5/14

424 857, 530351, 435 6951, 435419, 536 2352

The present invention provides biologically active variants of human α-2b-interferon. The variants contain carboxy terminus truncations when compared with the amino acid sequence of full-length human α-2b-interferon. It is the novel finding of the present invention that these truncated variants have the biological activity of full-length human α-2b-interferon. The invention encompasses these biologically active variant α-interferons, as well as polynucleotides encoding these interferons. Expression cassettes comprising these polynucleotides and host cells comprising the expression cassettes are also provided. The invention also provides compositions comprising variant α-interferon polypeptides and a pharmaceutically acceptable carrier.